ArticleJournal of applied toxicology : JAT2026
Pharmacokinetics and Acute Safety Evaluation of Tryptanthrin, A Bioactive Constituent of Indigo naturalis, Following Intravenous Administration in Mice.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The use of Indigo naturalis in treating inflammatory diseases is clinically restricted by severe adverse events, including pulmonary arterial hypertension and hepatotoxicity. Tryptanthrin, a major indoloquinazoline alkaloid of Indigo naturalis, exhibits potent anti-inflammatory activity; however, its specific safety profile relative to the crude extract remains unclear. This study aimed to elucidate the intravenous pharmacokinetics and acute safety of purified tryptanthrin to validate its potential as a safer pharmacological alternative. Following a single intravenous injection of 30 mg/kg-a dose range relevant to its pharmacological efficacy-in ICR mice, plasma concentrations were quantified using a validated LC-MS/MS method. Tryptanthrin exhibited rapid systemic distribution and biphasic elimination, characterized by a large volume of distribution (V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.